Abstract

THE IMPACT (SAFETY AND EFFICACY) OF BEVACIZUMAB ON PATIENTS WITH SOLID TUMORS EVALUATED BY A RETROSPECTIVE, MULTICENTRIC, PHASE IV STUDY

Prajakta Sanjay Bagul* and Vinod Patil

Abstract

It is a retrospective, multicentre, phase IV study to evaluate the safety and efficacy of Bevacizumab in patients with solid tumours. A systematic literature search was carried out to identify data collected from Phase IV study to evaluate the safety and efficacy of Bevacizumab used to treat solid tumours. Data from several phase IV studies from different centres was collected and analysed for different parameters like severity, EGOS performance scale etc. The angiogenesis inhibitor bevacizumab was the first or among the first available targeted therapies for a range of solid tumours. Improving overall and/or progression-free survival in patients with no or only limited treatment options besides chemotherapy, bevacizumab has changed the treatment paradigm and became a standard of care in the treatment of advanced cancers. Considering the vast and established evidence on the efficacy of bevacizumab in combination with chemotherapy and increasing evidence on further improved treatment outcomes when combined with other new treatments such as cancer immunotherapy or PARP inhibitors, bevacizumab is expected to remain a key agent in the treatment of cancer patients.

Keywords: Bevacizumab, Solid Tumours, Retrospective study, Safety.